EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Systemic and Pulmonary Hemodynamic Tolerability of Escalating Intravenous Epoprostenol Infusion in Isoflurane-Anesthetized Healthy Dogs

Shigeharu Semba, Ahmed Farag, Tomohiko Yoshida, Kazumi Shimada, Ryou Tanaka

Animals · 19.11.2026 · 16 (22) · 3679

DOI: 10.3390/ani16223679 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Animals, online erschienen am 19.11.2026. Verfasst von Shigeharu Semba und 4 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Continuous intravenous epoprostenol (prostacyclin, PGI2) is a cornerstone therapy for severe human pulmonary arterial hypertension, yet its hemodynamic safety profile in dogs remains incompletely defined. This study evaluated the systemic and pulmonary hemodynamic responses and acute tolerability of continuous intravenous epoprostenol titration in healthy, isoflurane-anesthetized dogs as a prerequisite for future pulmonary hypertension trials. Eight healthy beagle dogs were instrumented for invasive arterial and pulmonary arterial monitoring and received sequential escalating epoprostenol infusions at 1, 5, 10, 15, and 20 ng/kg/min (Epo1–Epo20; 30 min per step), followed by a 20 min washout period. All dogs completed the protocol without major complications. Systemic arterial pressures decreased in a dose-dependent manner, reaching statistical significance only at Epo20 (p < 0.05), without inducing clinically overt hypotension (mean arterial pressure < 60 mmHg). Cardiac output was preserved throughout, supported by a non-significant numerical increase in stroke volume (up to 25%) alongside a numerical reduction in systemic vascular resistance (up to 28%) and unchanged heart rate. Pulmonary arterial pressures, pulmonary vascular resistance, and oxygen delivery remained unchanged, whereas hemoglobin decreased modestly at Epo15 and Epo20 (p < 0.05). In conclusion, intravenous epoprostenol up to 20 ng/kg/min was systemically tolerated without overt hypotension, although pulmonary vasodilatory efficacy requires evaluation in dogs with pulmonary hypertension.

Zitieren

APA

Semba, S., Farag, A., Yoshida, T., Shimada, K., & Tanaka, R. (2026). Systemic and Pulmonary Hemodynamic Tolerability of Escalating Intravenous Epoprostenol Infusion in Isoflurane-Anesthetized Healthy Dogs. Animals, 16(22), 3679. https://doi.org/10.3390/ani16223679

Vancouver

Semba S, Farag A, Yoshida T, Shimada K, Tanaka R. Systemic and Pulmonary Hemodynamic Tolerability of Escalating Intravenous Epoprostenol Infusion in Isoflurane-Anesthetized Healthy Dogs. Animals. 2026;16(22):3679. doi:10.3390/ani16223679

BibTeX
@article{Semba2026,
  author = {Semba, Shigeharu and Farag, Ahmed and Yoshida, Tomohiko and Shimada, Kazumi and Tanaka, Ryou},
  title = {Systemic and Pulmonary Hemodynamic Tolerability of Escalating Intravenous Epoprostenol Infusion in Isoflurane-Anesthetized Healthy Dogs},
  journal = {Animals},
  year = {2026},
  volume = {16},
  number = {22},
  pages = {3679},
  doi = {10.3390/ani16223679}
}
Kostenlos starten →